IE47617B1 - Stilbene derivatives - Google Patents
Stilbene derivativesInfo
- Publication number
- IE47617B1 IE47617B1 IE2472/78A IE247278A IE47617B1 IE 47617 B1 IE47617 B1 IE 47617B1 IE 2472/78 A IE2472/78 A IE 2472/78A IE 247278 A IE247278 A IE 247278A IE 47617 B1 IE47617 B1 IE 47617B1
- Authority
- IE
- Ireland
- Prior art keywords
- formula
- group
- hydrogen
- tetrahydro
- tetramethyl
- Prior art date
Links
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 18
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 13
- 150000002367 halogens Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 6
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims abstract description 5
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract 16
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- -1 alkylenedioxymethyl Chemical group 0.000 claims description 22
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 239000005711 Benzoic acid Substances 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000005042 acyloxymethyl group Chemical group 0.000 claims description 3
- 229940007550 benzyl acetate Drugs 0.000 claims description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- LXNWFBFISUENQC-OBGWFSINSA-N ethyl 4-[(e)-2-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1\C=C(/C)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OC LXNWFBFISUENQC-OBGWFSINSA-N 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- CKTNHGVJKUQEBM-UHFFFAOYSA-N ethylazanide Chemical compound CC[NH-] CKTNHGVJKUQEBM-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 2
- 230000000552 rheumatic effect Effects 0.000 abstract description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 115
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 76
- 239000000243 solution Substances 0.000 description 72
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000000203 mixture Substances 0.000 description 30
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 235000011152 sodium sulphate Nutrition 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 19
- 239000000155 melt Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000001953 recrystallisation Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007858 starting material Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 10
- 239000012259 ether extract Substances 0.000 description 8
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 229910052987 metal hydride Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 239000001117 sulphuric acid Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 229960004217 benzyl alcohol Drugs 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- BHYVHYPBRYOMGC-UHFFFAOYSA-N ethyl 4-formylbenzoate Chemical compound CCOC(=O)C1=CC=C(C=O)C=C1 BHYVHYPBRYOMGC-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000004681 metal hydrides Chemical class 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 150000001733 carboxylic acid esters Chemical class 0.000 description 4
- 230000002140 halogenating effect Effects 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 150000004714 phosphonium salts Chemical class 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000004970 halomethyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- NLIUDONFMFYFRU-UHFFFAOYSA-M triphenyl-[1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethyl]phosphanium;bromide Chemical compound [Br-].C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(C)[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 NLIUDONFMFYFRU-UHFFFAOYSA-M 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- IWIWGFMIKABCFO-UHFFFAOYSA-N 1,1,3,3-tetramethyl-2h-indene Chemical compound C1=CC=C2C(C)(C)CC(C)(C)C2=C1 IWIWGFMIKABCFO-UHFFFAOYSA-N 0.000 description 2
- CCQKWSZYTOCEIB-UHFFFAOYSA-N 1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 CCQKWSZYTOCEIB-UHFFFAOYSA-N 0.000 description 2
- XBCVARFSRWLPOC-UHFFFAOYSA-N 1-(1,1,3,3-tetramethyl-2h-inden-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2C(C)(C)CC(C)(C)C2=C1 XBCVARFSRWLPOC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- KTFKRVMXIVSARW-UHFFFAOYSA-N 4-acetylbenzaldehyde Chemical compound CC(=O)C1=CC=C(C=O)C=C1 KTFKRVMXIVSARW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000006052 Horner reaction Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910000091 aluminium hydride Inorganic materials 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- NULUAKSYPPSJCO-FBMGVBCBSA-N ethyl 4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1\C=C(/C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 NULUAKSYPPSJCO-FBMGVBCBSA-N 0.000 description 2
- SXUXKYROSMWMBG-UHFFFAOYSA-N ethyl 4-formyl-2-methylbenzoate Chemical compound CCOC(=O)C1=CC=C(C=O)C=C1C SXUXKYROSMWMBG-UHFFFAOYSA-N 0.000 description 2
- JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SOHAVULMGIITDH-ZXPSTKSJSA-N (1S,9R,14E)-14-(1H-imidazol-5-ylmethylidene)-2,11-dimethoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7,10-tetraene-12,15-dione Chemical class C([C@]1(C2=CC=CC=C2N([C@@]21NC1=O)OC)C(C)(C)C=C)=C(OC)C(=O)N2\C1=C\C1=CNC=N1 SOHAVULMGIITDH-ZXPSTKSJSA-N 0.000 description 1
- BIUFXBHZCYSMPU-UHFFFAOYSA-N (3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methanol Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(CO)C(OC)=C2 BIUFXBHZCYSMPU-UHFFFAOYSA-N 0.000 description 1
- MJYPPHOWNYQAQX-DYTRJAOYSA-N (4-nitrophenyl)methyl 4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoate Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1C(=O)OCC1=CC=C([N+]([O-])=O)C=C1 MJYPPHOWNYQAQX-DYTRJAOYSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- RBACIKXCRWGCBB-UHFFFAOYSA-N 1,2-Epoxybutane Chemical compound CCC1CO1 RBACIKXCRWGCBB-UHFFFAOYSA-N 0.000 description 1
- BKNUXXFUQHTKHP-UHFFFAOYSA-N 1-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OC)=C2 BKNUXXFUQHTKHP-UHFFFAOYSA-N 0.000 description 1
- ASHGWDQRUMQKEY-UHFFFAOYSA-M 1-(3-methoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethyl-triphenylphosphanium;bromide Chemical compound [Br-].COC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(C)[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ASHGWDQRUMQKEY-UHFFFAOYSA-M 0.000 description 1
- IHUSZOMIBSDQTB-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(C(=O)C)=CC=2 IHUSZOMIBSDQTB-UHFFFAOYSA-N 0.000 description 1
- KDVZUARNRGKIKF-UHFFFAOYSA-N 1-(7-methoxy-1,1,3,3-tetramethyl-2h-inden-5-yl)ethanone Chemical compound COC1=CC(C(C)=O)=CC2=C1C(C)(C)CC2(C)C KDVZUARNRGKIKF-UHFFFAOYSA-N 0.000 description 1
- ZUGRLOSFUMNNDN-UHFFFAOYSA-M 1-(7-methoxy-1,1,3,3-tetramethyl-2h-inden-5-yl)ethyl-triphenylphosphanium;bromide Chemical compound [Br-].C=1C(C(CC2(C)C)(C)C)=C2C(OC)=CC=1C(C)[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ZUGRLOSFUMNNDN-UHFFFAOYSA-M 0.000 description 1
- PXSMPYKGNAUXBM-BMRADRMJSA-N 1-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1\C=C(/C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 PXSMPYKGNAUXBM-BMRADRMJSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XDTTUTIFWDAMIX-UHFFFAOYSA-N 3-methyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1[N+]([O-])=O XDTTUTIFWDAMIX-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- GWODBVDCNSWNFM-SAPNQHFASA-N [4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenyl]methanol Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(CO)C=C1 GWODBVDCNSWNFM-SAPNQHFASA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OFUCEQWVGVURAS-UHFFFAOYSA-N ethyl 4-(diethoxyphosphorylmethyl)benzoate Chemical compound CCOC(=O)C1=CC=C(CP(=O)(OCC)OCC)C=C1 OFUCEQWVGVURAS-UHFFFAOYSA-N 0.000 description 1
- ZAHKOEFDLWPFNE-BMRADRMJSA-N ethyl 4-[(e)-2-(1,1,2,3,3-pentamethyl-2h-inden-5-yl)prop-1-enyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1\C=C(/C)C1=CC=C2C(C)(C)C(C)C(C)(C)C2=C1 ZAHKOEFDLWPFNE-BMRADRMJSA-N 0.000 description 1
- UMJKMAVWRRMXHP-UHFFFAOYSA-N ethyl 4-formyl-3-methylbenzoate Chemical compound CCOC(=O)C1=CC=C(C=O)C(C)=C1 UMJKMAVWRRMXHP-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 201000006122 hypervitaminosis A Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002468 indanes Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940101545 mi-acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZKULOXDHSGQEQE-CZIZESTLSA-N n,n-diethyl-4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1\C=C(/C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 ZKULOXDHSGQEQE-CZIZESTLSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- ORVJTFDUQVNOBD-FBMGVBCBSA-N n-ethyl-4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1\C=C(/C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 ORVJTFDUQVNOBD-FBMGVBCBSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 1
- VBQCHPIMZGQLAZ-UHFFFAOYSA-N phosphorane Chemical class [PH5] VBQCHPIMZGQLAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- PEQVEWGYWQOOPU-UHFFFAOYSA-M triphenyl-[(1,1,3,3-tetramethyl-2h-inden-5-yl)methyl]phosphanium;chloride Chemical compound [Cl-].C=1C=C2C(C)(C)CC(C)(C)C2=CC=1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PEQVEWGYWQOOPU-UHFFFAOYSA-M 0.000 description 1
- FYPPFNIHEQRSSA-UHFFFAOYSA-M triphenyl-[1-(1,1,3,3-tetramethyl-2h-inden-5-yl)ethyl]phosphanium;bromide Chemical compound [Br-].C=1C=C(C(CC2(C)C)(C)C)C2=CC=1C(C)[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FYPPFNIHEQRSSA-UHFFFAOYSA-M 0.000 description 1
- SVPDQMCYGWKADZ-UHFFFAOYSA-M triphenyl-[1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)propyl]phosphanium;bromide Chemical compound [Br-].C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(CC)[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SVPDQMCYGWKADZ-UHFFFAOYSA-M 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
- C07C1/32—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero-atoms other than or in addition to oxygen or halogen
- C07C1/34—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero-atoms other than or in addition to oxygen or halogen reacting phosphines with aldehydes or ketones, e.g. Wittig reaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/47—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing ten carbon atoms
- C07C13/48—Completely or partially hydrogenated naphthalenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/34—Monohydroxylic alcohols containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/164—Unsaturated ethers containing six-membered aromatic rings
- C07C43/168—Unsaturated ethers containing six-membered aromatic rings containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/548—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
- C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
- C07C49/798—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
- C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C11/00—Fermentation processes for beer
- C12C11/02—Pitching yeast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds of the general formula wherein n is 1 or 2 and, when n is 1, R<1> and R<2> are hydrogen, alkoxy or halogen, or, when n is 2, R<1> is hydrogen, alkoxy or halogen and R<2> is hydrogen; R<3>, R<4>, R<5> and R<6> are hydrogen or alkyl; R<7> is hydrogen, methyl or ethyl; R<8> and R<9> are hydrogen, alkyl or halogen, and R10 is -(CH=CR<19>)m, in which m is zero or 1 and R<11> is or 2-oxazolinyl, or, when m is 1, also is hydrogen; R<12> is hydrogen or alkyl; R<13> is hydrogen, alkyl or -N(R<17>, R<18>) or -OR<14>; R<14> is hydrogen, alkyl or alkanoyl; R<15> is hydrogen, alkyl or -OR<16> or -(CH2)pN(R<17>, R<18>); R<16> is hydrogen, alkyl, hydroxy alkyl or optionally, substituted aryl, or aralkyl; R<17> and R<18> are hydrogen or alkyl or R<17> and R<18> together with the nitrogen atom form a heterocyclic group; R<19> is hydrogen or alkyl and p is zero, 1, 2 or 3; ketals and salts thereof are useful for the treatment of neoplasms, dermatological conditions and rheumatic illnesses.
Description
The present invention relates to stilbene derivatives. More particularly, the invention is concerned with stilbene derivatives, a process for the manufacture thereof and pharmaceutical preparations containing same. The invention is also concerned with intermediates occurring in said process.
The stilbene derivatives provided by the present invention are compounds of the general formula
, wherein n stands for 1 or 2 and, when n
2 stands for 1, R and R represent hydrogen, lower alkoxy or halogen, or, when n stands for 2, R1 represents hydrogen, lower alkoxy
3 or halogen and R represents hydrogen} R , 4 5 6
R , R and R represent hydrogen or lower alkyl; R represents hydrogen, methyl or
9 ethyl; R and R represent hydrogen, lower alkyl or halogen; and R^0 represents a group of the formula — (CH=CR18) R , in which 11 m stands for zero or 1 and R represents a group of the formula
R12 0 —(Lh—R13 or -C-R15 or the 2-oxazolinyl group, or, when m stands 12 for l,also represents hydrogen; R represents hydrogen or lower alkyl; R represents hydrogen, lower alkyl or a group of the formula -N(R17,R18) or -OR14; R14 represents hydrogen, lower alkyl or alkanoyl; 15
R represents hydrogen, lower alkyl or a group of the formula -OR15 or —(CH,) N(R17, z p
16
R ); R represents hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the 17 18 aryl portion; R and R represent
18 hydrogen or lower alkyl or R and R together with the nitrogen atom to which they are attached represent a heterocyclic 19 group; R represents hydrogen or lower alkyl and p stands for zero, 1, 2 or 3; as well as ketals of compounds of formula I in which R11 represents a group of the formula IS 15 —C(O)R and R represents hydrogen or lower alkyl, and salts of compounds of formula I.
As used in this Specification, the term, lower means that the groups qualified thereby contain up to 6 carbon atoms.
Alkyl and alkoxy groups can be straight-chain or branched-chain, examples of alkyl groups being the methyl, ethyl, isopropyl and 2-methylpropyl groups and examples of alkoxy groups being the methoxy, ethoxy and isopropoxy groups. Alkanoyl groups are derived, for example, from acetic acid, propionic acid or pivalic acid, or also from a higher carboxylic acid containing up to 20 carbon atoms (e.g. from palmitic acid or stearic acid). The phenyl group is a preferred aryl group. Examples of substituted aryl groups are hydroxy-, nitro- and halo-phenyl groups.
The benzyl group is a preferred aralkyl group. Examples of Σ7 18 heterocyclic groups denoted by —N(R ,R) are 5-membered or 6-membered nitrogen-containing heterocyclic rings which may contain an oxygen or sulphur atom or a further nitrogen atom (e.g. the piperidino, piperazino, morpholino, thiamorpholino and pyrrolidino groups). Examples of ketals are di(lower alkyl) ketals and lower alkylene ketals. The oxazolinyl group can be substituted by one or two lower alkyl groups. Of the halogen atoms, chlorine and bromine are preferred.
A preferred class of compounds of formula I hereinbefore comprises those in which, when n stands for 1, R^ and
R represent hydrogen, lower alkoxy or halogen, or, when n
4761 stands for 2, R1 represents hydrogen, lower alkoxy or halogen and R2 represents hydrogen; R3, r\ R3 and R3 7 represent hydrogen or lower alkyl; R represents hydrogen, 8 9 methyl or ethyl; R and R represent hydrogen, lower alkyl 5 or halogen; and R3-0 represents hydroxymethyl, alkoxymethyl alkanoyloxymethyl, carboxyl, alkoxycarbonyl, formyl, alkylenedioxymethyl, alkanoyl, carbamoyl, mono(lower alkyl) carbamoyl, di(lower alkyl)carbamoyl, N-heterocyclylcarbonyl or 2-oxazolinyl. Furthermore, compounds of formula 1 in which n stands for 2 are preferred, as are compounds of 1 2 5 6 8 9 formula I in which R , R , R , R , R and R represent 3 4 7 hydrogen and R , R and R represent methyl. A further preferred class of compounds of formula I comprises those in which R3-0 represents a group of the formula — (CifcCHJ^R3·3 especially when m stands for zero and, moreover, when R3-3represents lower alkoxycarbonyl, lower alkylcarbamoyl, lower alkoxymethyl or lower alkanoyloxymethyl.
According to the process provided by the present invention, the stilbene derivatives aforesaid (i.e. the compounds of formula I and their salts) are manufactured by reacting a compound of the general formula
with a compound of the general formula (III) wherein R
.10 and n have the significance given earlier, and either A represents a triarylphosphoniumalkyl group of the formula R-CH—P[Q]3® Y®, in which R represents a hydrogen atom or the methyl or ethyl group, Q represents an aryl group and Y represents the anion of an organic or inorganic acid, and B represents the formyl group? or A represents the formyl, acetyl or propionyl group and B represents a dialkoxyphosphinylalkyl group of the formula R-CH—P[Z]_, in which R has Ψ ·ί 0 the significance given earlier and Z represents a lower alkoxy group?
to give a compound of formula I and, if desired, functionally modifying the group R'
The aryl groups denoted by Q in the aforementioned triarylphosphoniumalkyl groups include all generally known aryl groups, but especially mononuclear aryl groups such as phenyl, lower alkyl-substituted phenyl or lower alkoxy-substituted phenyl (e.g. tolyl, xylyl, mesityl and p-methoxyphenyl). Of the inorganic acid anions denoted by Y the chloride, bromide and hydrosulphate ions are preferred and of the organic acid anions the tosyloxy ion is preferred
The alkoxy groups denoted by z in the aforementioned dialkylphosphinylalkyl groups are preferably lower alkoxy groups (i.e. alkoxy groups containing 1-6 carbon atoms such as the methoxy and ethoxy groups).
The starting materials of formula II, insofar as their preparation is not known or described hereinafter, can be prepared according tc known methods or in an analogous manner to the methods described hereinafter.
Compounds of formula II in which A represents a 1 2 formyl, acetyl or propionyl group and R and R represent hydrogen [oxo compounds of formula II] can be prepared, for example, by subjecting an indane derivative, which is substituted in the cyclopentene ring corresponding to the desired compound of formula I, or a tetrahydronaphthalene derivative, which substituted in the cyclohexene ring corresponding to the desired compound of formula I, to an acylation. This acylation can be carried out, for example, in the presence of a Lewis acid.
Suitable acylating agents are formaldehyde/hydrochloric acid, acetyl halides (e.g. acetyl chloride) and propionyl halides (e.g. propionyl chloride). The preferred Lewis acids are the aluminium halides such as aluminium trichloride. The acylation is conveniently carried out in a solvent, such as nitrobenzene or a chlorinated hydrocarbon such as methylene chloride. The acylation is preferably carried out at a temperature of from 0°C to about +5°C.
A resulting oxo compound of formula II in which R^ and
R each represent a hydrogen atom is reacted in accordance with the present invention with a phosphonate of formula III in which B represents a dialkoxyphosphinylalkyl group to 1 2 give a compound of formula I in which R and R each 10 represent a hydrogen atom.
The phosphonium salts of formula II in which A represents a 1-(triarylphosphonium)-(methyl or ethyl or propyl) group required for the reaction with an aldehyde of formula III in which B represents an oxo group can be prepared, for example, as follows:
An aforementioned oxo compound of formula II in which 1 2
R and R represent hydrogen is reduced to give a corresponding alcohol at about 0°C to about +5°C using a complex metal hydride (e.g. sodium borohydride in an alkanol or lithium aluminium hydride in an ether, tetrahydrofuran or dioxan). The resulting alcohol is subsequently halogenated in the presence of an amine base (e.g. pyridine) using a customary halogenating agent (e.g. phosphorus oxychloride or phosphorus tribromide). The halide Obtained is then reacted with a triarylphosphine in a solvent, preferably triphenylphosphine in toluene or xylene, to give a desired phosphonium salt of formula II.
Oxo compounds and phosphonium salts of formula II in 1 2 which R and R represent alkoxy or halogen can be prepared, 5 for example, by converting a corresponding phenol in a manner known per se into a corresponding alkoxy-substituted derivative of formula II by treatment with an alkylating agent (e.g. a lower alkyl halide or a lower alkanol in the presence of an acid agent).
The aforementioned phenols can be obtained, for example, as follows:
2
An oxo compound of formula II in which R and R represent hydrogen is nitrated by treatment with a mixture of concentrated nitric acid and concentrated sulphuric acid.
The nitro group which is preferentially introduced in the ortho-position to the formyl, acetyl or propionyl group is catalytically reduced in a manner known per se (e.g, with the aid of Raney-nickel) to the amino group which is replaced by the hydroxy group via the diazonium salt in a known manner.
If the diazonium salt prepared from the amine is treated in the warm with a copper (I) halide, then there is obtained the corresponding halo derivative of the oxo compound of formula II. By treating said halo derivative with nitric acid it is possible to introduce, in the meta-position to the formyl, acetyl or propionyl group, a nitro group which likewise can be replaced in the manner previously described by the hydroxy group or a halogen atom.
By converting the hydroxy group into an alkoxy group there can be obtained, if desired, ketones of formula II which carry similar or mixed substitution.
A halogen atom present on the aromatic nucleus can be removed, if desired, by reduction in a manner known per se.
The compounds of formula III in which B represents the formyl group can be prepared from phenyl derivatives which are nitro-substituted in the 1-position in the manner described in Chem. Berichten 102 (1969), pages 2502-2507.
They can also be prepared by reducing a corresponding p15 -carboxy substituted phenyl derivative. The reduction of the carboxyl group to the formyl group can be carried out, for example, with diisobutylaluminium hydride.
The compounds of formula III in which B represents a dialkoxyphosphinylmethyl group can be prepared from the aforementioned compounds of formula III in which B represents the formyl group by converting the formyl group using a metal hydride (e.g. sodium borohydride) into the hydroxymethyl group, halogenating the hydroxymethyl group using a customary halogenating agent (e.g. phosphorus tri25 chloride) and reacting the resulting halomethyl group with a trialkyIphosphite, especially triethylphosphite, to give a desired phosphonate of formula III.
A compound of formula III in which B represents the formyl group or a dialkoxyphosphinylmethyl group can be prepared by halogenating a corresponding phenyl derivative which is methyl-suhstituted in the 1-position and either reacting the resulting halomethyl derivative with a trialkylphosphite or hydrolysing said halomethyl derivative to the hydroxymethyl derivative and oxidising the latter by treatment with an oxidising agent (e.g. manganese dioxide).
The reaction of a compound of formula II with a compound of formula III in accordance with the process provided by the present invention can be carried out according to the known methods of the Wittig reaction or the Horner reaction. There are preferably used as the starting materials those compounds of formula III in which represents a group which is not reactive towards phosphoranes such as, in particular, the formyl group.
The functional modification of a group also in accordance with the process provided by the present invention, can comprise, for example, the conversion of the carboxyl group into a salt, an ester, an amide, an oxaline derivative or into the hydroxymethyl group which can subsequently be etherified or esterified. Another functional modification comprises the saponification of a carboxylic •Mi acid ester or the reduction thereof to the hydroxymethyl group. The hydroxymethyl group can also be oxidised to the formyl group. Compounds of formula I which contain a formyl group can be converted, e.g. by means of a Wittig reaction, into compounds of formula I in which R^° rep19 11 resents a group of the formula — (CH=CR )mR in which m
11 stands for 1, R represents hydrogen or alkyl and R represents alkoxymethyl, alkanoyloxymethyl, carboxyl, alkoxycarbonyl, alkanyl or alkenyl. All of these functional modifications can be carried out according to methods known per se.
In the case of the Wittig reaction, the starting materials are reacted with one another in the presence of an acid binding agent, for example, in the presence of a strong base such as butyl lithium, sodium hydride or the sodium salt of dimethyl sulphoxide, but preferably in the presence of an ethylene oxide which is optionally substituted by lower alkyl such as 1,2-butylene oxide, if desired in a solvent (e.g. an ether, such as diethyl ether or tetra20 hydrofuran or an aromatic hydrocarbon such as benzene, at a temperature between room temperature and the boiling point of the reaction mixture.
In the case of the Horner reaction, the starting materials are reacted with one another in the presence of a base and, preferably, in the presence of an inert organic solvent? for example, in the presence of sodium hydride in benzene, toluene, dimethylformamide, tetrahydrofuran, dioxan or 1,2-dimethoxyalkane or in the presence of a sodium alcoholate in an alkanol (e.g. sodium methylate in methanol) at a temperature between 0°C and the boiling point of the reaction mixture.
It has been found to be convenient in certain cases to carry out the aforementioned reactions in situ, i.e. to react the starting materials with one another without isolating the phosphonium salt or phosphonate in question from the medium in which it is prepared.
A carboxylic acid of formula I can be converted in a manner known per se (e.g. by treatment with thionyl chloride, preferably in pyridine, or phosphorus trichloride in toluene) into an acid chloride which can be converted by reaction with an alcohol into an ester or by reaction with an amine into a corresponding amide. Amides can be converted into amines in a manner known per se? for example, by reduction with complex metal hydrides such as lithium aluminium hydride.
A carboxylic acid ester of formula I can be hydrolysed in a manner known per se (e.g. by treatment with alkali, especially by treatment with aqueous-alcoholic sodium hydroxide or potassium hydroxide) at a temperature between room temperature and the boiling point of the mixture and the resulting carboxylic acid can then be amidated via an acid halide as described earlier. Alternatively, a carboxylic acid ester of formula I can be directly amidated as described hereinafter.
A carboxylic acid ester of formula I can be converted 5 directly into a corresponding amide, for example by treatment with lithium amide. The ester is advantageously treated with lithium amide at room temperature.
A carboxylic acid of formula I can be converted into an oxazoline derivative of formula I via a halide by reaction with 2-aminoethanol or 2-amino-2-methyl-1-propanol and subsequent cyclisation.
A carboxylic acid or carboxylic acid ester of formula I can be reduced in a manner known per se to give a corresponding alcohol of formula I. The reduction is advan15 tageously carried out using a metal hydride or alkyl metal hydride in an inert solvent. Especially suitable hydrides are the mixed metal hydrides such as lithium aluminium hydride or bis[raethoxy-ethylenoxy]-sodium aluminium hydride. Suitable solvents are, inter alia, ether, tetrahydrofuran or dioxan when lithium aluminium hydride is used and ether, hexane, benzene or toluene when diisobutylaluminium hydride or bis[methoxy-ethylenoxy]-sodium aluminium hydride is used.
An alcohol of formula I can be etherified with an alkyl halide (e.g. methyl iodide), for example, in the presence of a base, preferably sodium hydride, in an organic solvent such as dioxan, tetrahydrofuran, 1,2-dimethoxyethane or dimethylformamide, or in the presence of an alkali metal alcoholate in an alkanol, at a temperature between 0°C and room temperature.
An alcohol of formula I can be esterified by treatment with an alkanoyl halide or anhydride, conveniently in the presence of a base (e.g. pyridine or triethylamine) at a temperature range between room temperature and the boiling point of the mixture.
A carboxylic acid of formula I forms salts with bases, especially with alkali metal hydroxides and preferably with sodium hydroxide or potassium hydroxide.
The compounds of formula I occur predominantly in the 15 trans form. Cis isomers which may be obtained can be separated or isomerised to the trans isomers in a manner known per se where desired.
The stilbene derivatives provided by the present invention are pharmacodynamically valuable. They can be used for the topical and systemic therapy of benign and malignant neoplasms and of premalignant lesions as well as for the systemic and topical prophylaxis of the said conditions.
The present stilbene derivatives are also suitable for the topical and systematic therapy of acne, psoriasis and other dermatoses accompanied by an intensified or pathologically altered comification, as well as of inflammatory and allergic dermatological conditions. They can moreover be used for the control of mucous membrane diseases associated with inflammatory or degenerative or metaplastic changes.
Compared with known retinoids, the stilbene deriv10 atives provided by this invention are characterised in that they are active in extraordinarily slight amounts.
The tumour-inhibiting activity of the present stilbene derivatives is significant. In the papilloma test in mice, tumours induced with dimethylbenzanthracene and croton oil regress. In the case of the intraperitoneal administration of ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid ethyl ester, the diameter of the papilloma decreases in the course of 2 weeks by 75% at a dosage of 0.2 mg/kg/week, by 56% at a dosage of 0.1 mg/kg/week and by 48% at a dosage of 0.05 mg/kg/week. In the case of oral administration of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid ethyl ester to mice, the diameter of the induced tumours decreases in the course of 2 weeks (5 individual doses/week) by 63% at a dosage of 0.4 mg(5 x 0.08 mg)/kg/week, by 48% at a dosage of 0.2 mg (5 x 0.04 mg)/kg/week and by 37% at a dosage of 0.05 mg (5 x 0.01 mg)/kg/week.
4761
The stilbene derivatives provided by this invention can also be used for the oral treatment of rheumatic illnesses, especially those of an inflammatory or degenerative kind which attack the joints, muscles, tendons and other parts of the motor apparatus. Examples of such illnesses are rheumatic arthritis, Bechterew's spondylarthritis ankyl· poetica and psoriatic arthropathy.
For the treatment of these illnesses, the present stilbene derivatives are administered orally, the dosage in the case of adults conveniently being about 0.01-1 mg/kg body weight per day, preferably 0.05-0.5 mg/kg/day. A possible over-dosage can manifest itself in the form of a vit-A hypervitaminosis which can readily be recognised from its symptoms (scaling of the skin, hair loss).
The dosage can be administered as a single dosage or in several sub-divided dosages.
The stilbene derivatives provided by the present invention can therefore be used as medicaments, for example in the form of pharmaceutical preparations which contain them in association with a carrier material.
The pharmaceutical preparations suitable for systemic administration can be produced, for example, by adding a compound of formula I or a salt thereof as the active ingredient to non-toxic, inert, solid or liquid carriers which are conventionally used in such preparations.
The pharmaceutical preparations can be administered enterally, parenterally or topically. Suitable preparations for enteral administration are, for example, tablets, capsules, dragees, syrups, suspensions, solutions and suppositories. Suitable preparations for parenteral administration are infusion or injection solutions.
The dosages in which the present stilbene derivatives are administered can vary according to the particular dosage form and mode of administration as well as according to the requirements of the patient.
The stilbene derivatives of this invention can be administered in amounts of ca 0.01 mg to ca 5 mg daily in one or more dosages. A preferred form of administration comprises capsules containing ca 0.1 mg to ca 1.0 mg of active ingredient.
The pharmaceutical preparations can contain inert as well as pharmacodynamically active additives. Tablets or granulates, for example, can contain binding agents, filling agents, carrier substances or diluents. Liquid preparations can take the form of, for example, sterile solutions which are miscible with water. Capsules can contain, in addition to the active ingredient, a filling agent or thickening agent. Furthermore, flavour-improving additives, substances normally used as preservatives, stabilisers, wetting agents and emulsifying agents as well as salts for varying the osmotic pressure, buffers and other additives may also he present in the pharmaceutical preparations.
The aforementioned carrier substances and diluents can be organic or inorganic in nature; for example, water, gelatin, lactose, starch, magnesium stearate, talc, gum arabic, polyaikyleneglyeols and the like. A prerequisite is that all adjuvants used in the production of the pharmaceutical preparations are non-toxic.
For topical administration, the pharmaceutical preparations are conveniently provided in the form of ointments, tinctures, creams, solutions, lotions, sprays, suspensions and the like. Ointments, creams and solutions are preferred. These pharmaceutical preparations for topical administration can be produced by mixing the present stilbene derivatives with non-toxic, inert, solid or liquid carriers which are customary per se in such preparations and which are suitable for topical administration.
For topical administration there are suitably used ca 0.001% to ca 0.3%, preferably 0.002% to 0.1%, solutions, as well as ca 0.002% to ca 0.5%, preferably ca 0.002%, to ca 0.1%, ointments or creams.
The pharmaceutical preparations may contain an antioxidant (e.g. tocopherol, N-methyl-Y-tocopheramine, butylated hydroxyanisole or butylated hydroxytoluene).
> 47617
The following Examples illustrate the process provided by the present invention:
Example 1
300 ml of butylene oxide are added to 30.5 g of [15 -(1,1,3,3-tetramethyl-5-indanyl)ethyl]-triphenyIphosphonium bromide and 8 g of 4-ethoxyoarbonylbenzaldehyde and the mixture is then stirred at 65°C for 12 hours in an inert gas atmosphere. The resulting clear solution is cooled, introduced into ca 500 ml of ice/water and extracted twice with hexane. The organic extract is extracted three times with methanol/water, dried over sodium sulphate and concentrated under reduced pressure. The residue is purified by adsorption on silica gel using hexane/ether (19:1) for the elution. The p-[(E)-2-(l,l,3,3-tetramethyl-5-indanyl)15 -propenyl]-benzoic acid ethyl ester obtained from the eluate melts at 7O°-71°C after reerystallisation from ether/hexane.
The [1-(1,1,3,3-tetramethyl-5-indanyl)ethyl]-tripheny Iphosphonium bromide used as the starting material can be prepared, for example, as follows:
87.8 g of acetyl chloride are dissolved in 240 ml of nitrobenzene. 149.2 g of aluminium chloride are introduced portionwise into the solution. The mixture is cooled down to 0°-5°C and then treated dropwise while cooling well with a solution of 195.0 g of 1,1,3,3-tetramethyl-indane in 360 ml of nitrobenzene. The temperature should not rise above 5°C. The mixture is stirred at 0°C for 15 hours, then introduced into 3 litres of ioe/water and extracted with ether. The ether extract is washed'twice with a 2-N sodium hydroxide solution and twice with a saturated sodium chloride solution, dried over sodium sulphate and concentrated, firstly in a water-jet vacuum and then in a high vacuum to remove the nitrobenzene. The residual oily (1,1,3,3-tetramethyl-5-indanyl)-methyl ketone boils at 100°-103°C/0.5 Torr.
2.66 g of lithium aluminium hydride are treated with 40 ml of absolute ether. While cooling to 0°-5°C there are added dropwise within 30 minutes 26 g of 1,1,3,3-tetramethyl-5-indanyl methyl ketone. After a further 30 minutes, the mixture is cautiously treated dropwise with 25 ml of a saturated sodium sulphate solution. The solution is filtered. The filtrate is washed once with a 1-N sodium hydroxide solution and twice with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure to remove the solvent. The residual oily a-l,l,3,3-pentamethyl-5-indane-methanol, which is uniform according to thin-layer chromatography [flow agent: hexane/ether (80:20)], is immediately processed as follows:
24.0 g of a-l,l,3,3-pentamethyl-5-indane-methanol are dissolved in 20 ml of absolute ether and 100 ml of absolute hexane. After the addition of 2 drops of pyridine, the solution is treated dropwise over a period of 30 minutes with 16.2 g of phosphorus tribromide dissolved in 80 ml of absolute hexane. After stirring at 0°-5°C for a further hour, the product is introduced into ice/water and exhaustively extracted with ether. The ether extract is washed twice with a saturated sodium bicarbonate solution and twice with a sodium chloride solution, dried over sodium sulphate and evaporated under reduced pressure to remove the solvent. The residual oily 5-(1-bromoethy1)-1,1,3,310 -tetramethyl-indane, which is uniform according to thin-layer chromatography [flow agent: hexane/ether (95:5)], is immediately processed as follows:
26.3 g of triphenylphosphine are dissolved in 120 ml of xylene. . The solution is treated with 30.9 g of 5-(1-bromoethyl)-l,l,3,3-tetramethyl-indane dissolved in 60 ml of xylene. The mixture is warmed to 100°C while stirring and left at this temperature for 12 hours. The thick-oily
1-(1,1,3,3-tetramethy1-5-indanyl)ethyl-triphenylphosphonium bromide which thereby separates out and which crystallises after seeding melts at 151°-156°C after recrystallisation from methylene chloride/toluene (crystals contain 0.3 equivalents of toluene).
Example 2
2,4 g of 1,1,3,3-tetramethy1-5-indanyl methyl ketone and 3.4 g of 4-[(diethoxyphosphinyl)methyl]-benzoic acid ethyl ester are dissolved in 7 ml of dimethylformamide.
The solution is treated dropwise under argon at room temperature while stirring with a sodium ethanolate solution (prepared from 0.33 g of sodium and 7 ml of ethanol) and subsequently stirred at 70°C for 18 hours. The mixture is subsequently introduced into ice/water and extracted with ether. The ether extract is washed with a saturated sodium chloride solution, dried over sodium sulphate and evaporated under reduced pressure. The residual p-[(E)-2-(1,1,3,310 -tetramethyl-5-indanyl)propenyl]-benzoic acid ethyl ester, a brown oil, is purified by adsorption on silica gel using hexane/ether (9:1) for the elution. The ester melts at 7O°-71°C after recrystallisation from hexane/ether.
Example 3
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)ethyl]-triphenylphosphonium bromide and 4-ethoxycarbonyl-benzaldehyde there can be obtained ρ-[ (E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester of melting point 9O°-91°C.
The [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)ethyl]-triphenylphosphonium bromide used as the starting material oan be prepared in a manner analogous to that described in Example 1, from 5,6,7,8-tetrahydro-5,5,8,
8-tetramethyl-naphthalene via (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)methyl ketone, 5,6,7,8-tetrahydro47617
-a-5,5,8,8-pentamethyl-2-naphthalene-methanol and 2-(bromo· ethyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene.
Example 4
In a manner analogous to that described in Example 1 5 from [l-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)ethyl]-triphenylphosphonium bromide and 4-ethoxyoarbonyl-benzaldehyde there can be obtained p-[(E)-2-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester of melting point 97°-98°C.
The [1-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)ethyl]-triphenylphosphonium bromide used as the starting material can be prepared in a manner analogous to that described in Example 1, from 3-methoxy15 -5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene via (3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)methyl ketone, 3-methoxy-5,6,7,8-tetrahydro-5,5,
8,8-tetramethyl-2-naphthalene-methanol and 2-(1-bromoethyl) -3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphtha20 lene.
Example 5
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) ethyl]-triphenylphosphonium bromide and 3-methyl-4-ethoxycarbonyl-benzaldehyde there can be obtained ρ-[(E)-2-(5,6,7, 8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-2-methyl-benzoic acid ethyl ester as a colourless oil which is uniform according to thin-layer chromatography, (Rf = 0.6; hexane/15% ether).
The aforementioned 3-methyl-4-ethoxycarbonyl-benzaldehyde can be prepared from 4-nitro-3-methyl-benzoic acid in a manner analogous to that described for the preparation of 2-methyl-4-ethoxycarbonyl-benzaldehyde by Huneck et al in Chem. Ber. 102, 2502-2507 (1969).
Example 6
In a manner analogous to that described in Example 1, from [1-(1,1,2,3,3-pentamethyl-5-indanyl)ethyl]-triphenyl15 phosphonium bromide and 4-ethoxycarbonyl-benzaldehyde there can be obtained p-[(E)-2-(1,1,2,3,3-pentamethyl-5-indanyl)propenyl]-benzoic acid ethyl ester of melting point 79°-80°C.
Example 7 in a manner analogous to that described in Example 1, from [1-(7-methoxy-1,1,3,3-tetramethyl-5-indanyl)ethyl]-triphenylphosphonium bromide and 4-ethoxycarbonyl-benzaldehyde there can be obtained p-[(E)-2-(7-methoxy-l,l,3,347617
-tetramethy1-5-indanyl)-propenyl]-benzoic acid ethyl ester of melting point 72°-73°C.
The [1-(7-methoxy-l,l,3,3-tetramethyl-5-indanyl)ethyl]-triphenylphosphonium bromide used as the starting material can be prepared, for example, as follows:
84.3 g of (1,1,3,3-tetramethy1-5-indanyl) methyl ketone (prepared as described in Example 1) are dissolved in 160 ml of concentrated sulphuric acid and the solution is cooled down to -20°C. At this temperature there is added during 10 minutes the nitrating acid prepared from 40 ml of concentrated nitric acid and 80 ml of concentrated sulphuric acid. After completion of the addition, the thick paste is immediately poured on to ice and extracted twice with ether. The ether extract is washed with a sodium bicarbonate solution and a sodium chloride solution, dried over sodium sulphate and freed from solvent under reduced pressure.
The separated (6-nitro-l,1,3,3-tetramethy1-5-indanyl) methyl ketone melts at 111°-112°C after recrystallisation from ether/hexane.
75.8 g of (6-nitro-l,1,3,3-tetramethy1-5-indanyl) methyl ketone are dissolved in 1500 ml of methanol and the solution is hydrogenated at 45°C for 48 hours under nitrogen with the aid of 20 g of Raney-nickel. 15 litres of hydrogen are taken up. The solution is then filtered through Speedex and the solvent is removed under reduced pressure. The separated (6-amino-l,l,3,3-tetramethyl-5-indanyl) methyl ketone melts at 161°-162°C after recrystallisation from ether/hexane.
113.1 g of (6-amino-l,l,3,3-tetramethyl-5-indanyl) methyl ketone are suspended in 2260 ml of 20% hydrochloric acid and the suspension is cooled down to 0°-5°C. The cold mixture is treated dropwise within 10 minutes with a solution of 33.9 g of sodium nitrite in 115 ml of water and the resulting solution is stirred for 30 minutes. The cold solution is subsequently introduced dropwise over a period of 2 hours while stirring into a solution of 243.2 g of copper (I) chloride in 250 ml of water and 250 ml of concentrated hydrochloric acid, which is wanned to 4O°-45°C. The mixture is then cooled down, introduced into ice-water and extracted three times with methylene chloride. The organic extract is washed with a sodium chloride solution, dried over sodium sulphate and freed from solvent under reduced pressure. The residue is purified by adsorption on silica gel using hexane/acetone (19:1) for the elution. The (6-chloro-l,l,3,3-tetramethyl-5-indanyl) methyl ketone obtained from the eluate melts at 69°-71°C after recrystallisation from hexane/ether.
In an analogous manner, from (6-chloro-l,l,3,3-tetramethyl-5-indanyl) methyl ketone there can be obtained (6-chloro-7-nitro-l,l,3,3-tetramethyl-5-indanyl) methyl ketone of melting point 119°-12O°C, and from (6-chloro-7-nitro617
-l,l,3,3-tetramethyl-5-indanyl) methyl ketone there can be obtained (6-chloro-7-amino-l,1,3,3-tetramethyl-5-indany1) methyl ketone of melting point 116°-117°C.
21.1 g of (6-chloro-7-amino-l,l,3,3-tetramethyl-5-indanyl) methyl ketone are introduced into 48 ml of concentrated sulphuric acid and, after the warming to 50°C, the mixture is treated slowly with 140 ml of distilled water. After cooling down to 0°-5°C, there is introduced dropwise into the mixture over a period of 45 minutes a solution of
.5 g of sodium nitrite in 20 ml of water. The resulting cold mixture is introduced dropwise while stirring over a period of 2 hours into a solution, held at 70°C, of 60 ml of water and 60 ml of concentrated sulphuric acid. The mixture is cooled, then introduced into ice-water and extracted three times with ether. The organic phase is washed with a sodium chloride solution, dried over sodium sulphate and freed from solvent under reduced pressure.
The residue is purified by adsorption on silica gel using hexane/ether (19:1) for the elution. The (6-chloro-7-hydroxy-l,l,3,3-tetramethyl-5-indanyl) methyl ketone obtained from the eluate melts at 78°-8O°C after recrystallisation from hexane/ether.
4.4 g of (6-chloro-7-hydroxy-l,l,3,3-tetramethyl-5-indanyl) methyl ketone are dissolved in 10 ml of dimethylformamide. The solution is treated first with 1.1 g of potassium hydroxide (dissolved in 1.2 ml of water) and then with 5.5 ml of methyl iodide and the resulting mixture is subsequently stirred at room temperature for 3 hours. The mixture is introduced into ice-water and extracted twice with ether. The organic extract is washed several times with a sodium chloride solution, dried over sodium sulphate and freed from solvent under reduced pressure. The separated (6-chloro-7-methoxy-l,1,3,3-tetramethyl-5-indanyl) methyl ketone melts at 59°-6O°C after reerystallisation.
g of (6-chloro-7-methoxy-l,l,3,3-tetramethyl-5-indanyl) methyl ketone are dissolved in ca 200 ml of methanol and, after the addition of 10 g of triethylamine and 2.5 g of 5% palladium/carbon catalyst, the mixture is hydrogenated at room temperature. 1 mol equivalent of hydrogen is taken up over a period of 5 hours. The solution is filtered over Speedex. The filtrate is evaporated. The residue is dissolved in water/ether and extracted several times with ether. The organic extract is washed with sodium chloride solution, dried over sodium sulphate and freed from solvent under reduced pressure.
The separated (7-methoxy-l,l,3,3-tetramethyl-5-indanyl) methyl ketone melts at 76°-77°C after reerystallisation from hexane.
In a manner analogous to that described in Example 1, from (7-methoxy-1,1,3,3-tetramethyl-5-indanyl) methyl ketone via 7-methoxy-a-1,1,3,3-pentamethyl-5-indane-methanol and
-(1-bromoethyl)-7-methoxy-l,1,3,3-tetramethyl-indane there can be obtained [1-(7-methoxy-l,1,3,3-tetramethy1-5-indanyl)ethyl]-triphenylphosphonium bromide of melting point 209°-210°C.
Example 8
In a manner analogous to that described in Example 1, from [(1,1,3,3-tetramethyl-5-indanyl)methyl]-triphenylphosphonium chloride and 4-ethoxycarbonyl-benzaldehyde there can be obtained p-[(E)-2-(1,1,3,3-tetramethy1-5-indanyl)vinyl]-benzoic acid ethyl ester of melting point 151°-152°C.
The [(l,l,3,3-tetramethyl-5-indanyl)methyl]-triphenylphosphonium chloride used as the starting material can be prepared, for example, as follows:
34.2 g of 1,1,3,3-tetramethyl-indane, 150 ml of glacial acetic acid, 300 ml of concentrated hydrochloric acid and 77 ml of formaldehyde solution (35%) are warmed to 75°-78°C while stirring for 2 hours. A further 7.7 ml of 35% formaldehyde solution are then added dropwise within 10 minutes. The mixture is held at the same temperature for 15 hours, then cooled down, introduced into ca 1 litre of ice-water and exhaustively extracted with toluene. The organic phase is washed neutral with water, dried over sodium sulphate and evaporated under reduced pressure. The resulting crude product, a reddish oil, is distilled over a Vigreux column. The pure 5-chloromethy1-1,1,3,3-tetramethy 1-indane boils at 143°-146°C/19 mmHg.
In a manner analogous to that described in Example 1, from 5-chloromethyl-l,l,3,3-tetramethyl-indane and triphenylphosphine there can be obtained [1-(1,1,3,3-tetramethy 1-5-indanyl) methyl] -triphenylphosphonium chloride.
Example 9
In a manner analogous to that described in Example 1, from [1-(1,1,3,3-tetramethyl-5-indanyl)ethyl]-triphenylphosphonium bromide and 4-acetyl-benzaldehyde there can be obtained 4'-[(E) —2—(1,1,3,3-tetramethy1-5-indanyl)propenyl]10 -acetophenone of melting point 13O°-131°C.
Example 10 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester (prepared as described in Example 3) are dissolved in 500 ml of ethanol at 45°C and the resulting solution is treated dropwise while stirring with a solution of 20 g of potassium hydroxide in 50 ml of water. The mixture is stirred at 55°C for 18 hours, then cooled, introduced into ice/water, acidified to pH 2 with 3-N sulphuric acid and extracted twice with methylene chloride. The methylene chloride extract is washed with a saturated sodium chloride solution, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residual ρ-[(E)-2-(5,6,7,8-tetrahydro- 5 ,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid melts at 247°-248°C after recrystallisation from methylene chloride/hexane.
Example 11
Into a suspension of 7,0 g of p-[(E)-2-(5, 6,7,8-tetra5 hydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid (prepared as described in Example 10) in 40 ml of absolute ether are introduced dropwise, after addition of 1.8 ml of pyridine, while stirring at 0°-5°C 3.5 ml of thionyl chloride. After the addition of 5 drops of Ν,Ν-dimethyΙΙΟ formamide, the solution is warmed to room temperature, stirred for 18 hours and then decanted off. The clear yellow solution of the acid chloride is introduced dropwise under argon into a solution of 3 ml of ethylamine in 20 ml of absolute ether. The mixture is stirred at room temperature for 2 hours, then introduced into a saturated sodium chloride solution and extracted twice with ether.
The ether extract is washed with a saturated sodium chloride solution, dried over anhydrous sodium sulphate and evaporated under reduced pressure. The residual p-[ (E)-2-(5,6,7,
8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid monoethylamide melts at 177°-178.5°C after recrystallisation from methylene chloride/hexane.
Example 12
11.3 g of ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetra25 methy1-2-naphthyl)propenyl]-benzoic acid ethyl ester (prepared as described in Example 3) dissolved in 20 ml of absolute ether and 20 ml of absolute tetrahydrofuran are introduced dropwise at 0°-5°C into a suspension of 1.33 g of lithium aluminium hydride in 20 ml of absolute ether. The solution is stirred at room temperature for 12 hours under an inert gas, then treated dropwise at 0°-5°C with 5 ml of a saturated sodium sulphate solution and filtered over Speedex. The filtrate is diluted with ether and washed once with a saturated sodium bicarbonate solution and twice with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure. The separated ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl alcohol melts at 123°-124°C after reerystallisation from methanol/ether.
Example 13
.8 ml of acetyl chloride are introduced dropwise at ca 5°C while stirring into a suspension of 6.6 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl alcohol (prepared as described in Example 12) in 10 ml of ether and 10 ml of pyridine. The mixture is stirred at room temperature for 3 hours, then introduced into ca 100 ml of ice/water and extracted three times with ether. The ether extract is washed once with 1-N hydrochloric acid and three times with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure. The separated p-[(E)-247617
-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzyl acetate melts at 100°-101°C after recrystallisation from ether.
Example 14
.0 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl) propenyl] -benzyl alcohol (prepared as described in Example 12) dissolved in 25 ml of dimethylformamide are introduced into a solution of 0.4 g of sodium hydride in 10 ml of dimethylformamide. After stirring at room temperature for 1 hour, the mixture is treated with 4.3 g of methyl iodide and the resulting mixture is stirred for a further 2 hours. The solution is then introduced into ca 200 ml of ice/water and extracted three times with ether.
The ether extract is washed three times with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure. The separated p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzyl methyl ether melts at 55°-56°C after recrystallisation from ether.
Example 15
3.48 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid (prepared as described in Example 10) are suspended in 12 ml of toluene. After the addition of 3.57 g of thionyl chloride, the suspension is stirred at 50°C for 12 hours and then evaporated to dryness under reduced pressure. The residue is dissolved in 6 ml of methylene chloride. The solution is introduced dropwise at 0°C into a solution of 2.3 g of
2-amino-2-methyl-l-propanol in 6 ml of methylene chloride. The white suspension is stirred at room temperature for 2.5 hours, diluted with ethyl acetate, washed three times with water, dried over sodium sulphate and concentrated under reduced pressure. The white crystalline residue is suspended in 20 ml of ether and treated dropwise at 0°C with 6 g of thionyl chloride. The white suspension is stirred at room temperature for 30 minutes and then treated cautiously with a saturated sodium carbonate solution until the pH value amounts to ca 9. The now clear solution is diluted with ether. The ether phase is washed three times with a saturated sodium chloride solution, dried over sodium sulphate and evaporated under reduced pressure. The residual 2-/~p-C(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl) propenyl] -phenyl_7-4,4-dimethy1-2-oxazoline melts at 115e-116°C after reerystallisation from ether.
Example 16
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthy1)propyl]-triphenylphosphonium bromide and 4-ethoxycarbonyl-benzaldehyde there can be obtained ρ-[(E)-2-(5,6,7,8-tetra47617 hydro-5,5,8,8-tetramethyl-2-naphthyl)-1-butenyl]-benzoic acid ethyl ester of melting point 82°-83°C.
The [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propyl]-triphenylphosphonium bromide used as the starting material can be obtained in a manner analogous to that described in Example 1 from 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene and propionic acid chloride.
Example 17
In a manner analogous to that described in Example 11, 10 from p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid and diethylamine there can be obtained p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid diethylamide of melting point 111°-112°C.
Example 18
In a manner analogous to that described in Example 11, from ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid and morpholine there can be obtained ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-220 -naphthyl)propenyl]-benzoic acid morpholide of melting point 143°-144°C.
Example 19
In a manner analogous to that desoribed in Example 11, from ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid and isopropanol there can be obtained p-[(E)-2-(5,6,7,8-tetrahydro~5,5,8,8-tetramethy 1-2-naphthyl)propenyl]-benzoic acid isopropyl ester of melting point 119°-12O°C.
Example 20
In a manner analogous to that described in Example 11, 10 from p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid and 2-diethylamino-ethanol there can be obtained p-[ (E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid 2-diethylamino-ethyl ester of melting point 65°-66°C.
Example 21
6.7 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl)propenyl]-benzyl alcohol (prepared as described in Example 12) dissolved in 100 ml of absolute ether are added dropwise within 10 minutes to a stirred suspension, cooled to 0°-5°C, of manganese dioxide in 100 ml of absolute ether. The mixture is stirred at room temperature overnight and then filtered through Celite. The filtrate is concentrated to dryness on a rotary evaporator.
4-7617
The yellowish oil crystallises. Recrystallisation from ether yields p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl) propenyl] -benzaldehyde in the form of colourless crystals of melting point 140°-141°C.
Example 22
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)ethyl]-triphenylphosphonium bromide and 4-acetyl-benzaldehyde there can be obtained 4'-[(E)-2-(5,6,7,8-tetra10 hydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-acetophenoneof melting point 148°-149°C.
Example 23
3.0 g of 4'-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl)propenyl]-acetophenone (prepared as des15 cribed in Example 22) dissolved in 40 ml of benzene are treated with a catalytic amount of p-toluenesulphonic acid and 0.6 g of ethyleneglycol and warmed in a Dean-Stark apparatus, the water formed being concurrently separated off. After heating under reflux for 2 days, the mixture is cooled down, introduced into ice/saturated sodium bicarbonate solution and exhaustively extracted with ether. The ether extract is washed twice with a saturated sodium chloride solution, dried over sodium sulphate and evaporated under reduced pressure to remove the solvent. The oily residue is purified by adsorption on silica gel using hexane/ether (9:1) for the elution. The 2-methyl-2-/—p_
- [(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) propenyl]-pheny1_71r3-dioxolane obtained from the eluate melts at 122°-123°C after reerystallisation from ether.
Example 24
1.0 g of sodium borohydride is cautiously added portionwise at 0°-5oC to 10.4 g of 4'-[(E)-2-(5,6,7,8-tetra hydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-acetophenone (prepared as described in Example 22) dissolved in 100 ml of absolute methanol. The solution is stirred at 0°C for 1 hour and at room temperature for 2 hours, then introduced into ice/water and exhaustively extracted with ether. The ether solution is washed twice with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure. The separated a-methyl-p- [ (E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) propenyl]-benzyl alcohol melts at 121°-123°C after crystallisation from ether.
Example 25
In a manner analogous to that described in Example 14, from α-methy1-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl alcohol there can be obtained 1,2,3,4-tetrahydro-6-[(E) -p-(l-methoxyethyl)-a47617
-methyl-styryl]-1,1,4,4-tetramethylnaphthalene of melting point 88°-89°C.
Example 26
In a manner analogous to that described in Example 13, 5 from α-methyl-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl alcohol there can be obtained α-methyl-p-[ (E) - 2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzyl acetate of melting point 85°-86°C.
Example 27
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)ethyl]-triphenylphosphonium bromide and 4-methy1-benzaldehyde there can be obtained 6-[(E)-p,a-dimethylstyryl]15 -1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene of melting paint 84°-85°C.
Example 28
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthy1)20 ethyl]-triphenylphosphonium bromide and 4-isopropy1-benzaldehyde there can be obtained 6-[(E)-p-isopropyl-a-methyls tyry 1]-1,2,3,4-tetrahydro-l,1,4,4-tetramethylnaphthalene of melting point 86°-87°C.
4761
Example 29
In a manner analogous to that described in Example 1, from [1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)ethyl]-triphenylphosphonium bromide and 2,4-dimethy1-benz5 aldehyde there can be obtained 6-[(E)-a,2,4-trimethylstyryl] -1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene of melting point 54°-56eC.
Example 30
In a manner analogous to that described in Example 1, 10 but preferably with a longer reaction time, from methy1-triphenylphosphonium bromide and ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzaldehyde (prepared as described in Example 21) there can be obtained
1.2.3.4- tetrahydro-1,1,4,4-tetramethyl-6-[(E)-a-methyl-p15 -vinylstyryl]naphthalene of melting point 94°-95°C.
Example 31
In a manner analogous to that described in Example 1, but preferably with a longer reaction time, from ethyl-triphenylphosphonium bromide and ρ-[(E)-2-(5,6,7,8-tetra20 hydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzaldehyde (prepared as described in Example 21) there can be obtained
1.2.3.4- tetrahydro-l,1,4,4-tetramethy1-6-[(E)-a-methyl-p-allylstyryl]naphthalene of melting point 64°-66,’C.
7 617
Example 32 g of p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetra~ methyl-2-naphthyl)propenyl]-benzaldehyde (prepared as desoribed in Example 21) and 1.4 g of diethyIphosphonoacetic acid ethyl ester are dissolved in 5 ml of dimethylformamide. A sodium alcoholate solution (prepared using 6.16 g of sodium in 3 ml of absolute alcohol) is added thereto at room temperature while stirring. After stirring at room temperature for 18 hours, the mixture is poured into ice10 -cold 1-N hydrochloric acid and exhaustively extracted with ether. The ether phases are washed with saturated sodium bicarbonate solution and sodium chloride solution and, after drying over anhydrous sodium sulphate, are concentrated under reduced pressure. The residue is purified by adsorption on silica gel using hexane/ether (19:1) for the elution. The (E)-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-cinnamic acid ethyl ester obtained from the eluate melts at 126°-127°C after recrystallisation from hexane/ether.
Example 33
In a manner analogous to that described in Example 11, from ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]-benzoic acid and benzyl chloride there can be obtained p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetra25 methy1-2-naphthyl)propenyl]-benzoic acid benzyl ester of melting point 113°-114°C.
4761
Example 34
In a manner analogous to that described in Example 11 from ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid and 4-nitro-benzaldehyde there can be obtained 4-nitrobenzyl p-[(E)-2-(5,6,7,8-tetrahydro-5 , 5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoate of melting point 183°-184°C.
Example 35
In a manner analogous to that described in Example 11, 10 from p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid and .ethyleneglycol there can be obtained 2-hydroxyethyl ρ-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoate of melting point 138°-139°C.
Example 36 ml of a 20% solution of dibutylaluminium hydride in hexane are added dropwise at room temperature under an inert gas atmosphere and while stirring to a solution of 14.1 g of ρ—[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) propenyl]-(E)-cinnamic acid ethyl ester (prepared as described in Example 32) in 70 ml of absolute hexane and the mixture is stirred overnight. The solution is then treated dropwise at Q°-5°C with 50 ml of methanol and filtered over
Speedex. The filtrate is diluted with ether, washed once with a saturated sodium bicarbonate solution and twice with a saturated sodium chloride solution, dried over sodium sulphate and concentrated under reduced pressure. The separated 3-p-/~[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl) propenyl] pheny 1_7” (E)-2-propen-l-ol melts at 109°-110°C after recrystallisation from hexane.
Example 37
In a manner analogous to that described in Example 13, 10 from 3-p-/~[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]pheny1_7~(E)-2-propan-l-ol there can be obtained 3-p-/ [(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy 1-2-naphthyl) propenyl]phenyl_7“2”Propen-l-yl acetate of melting point 109°-ll0°C.
Example 38
In a manner analogous to that described in Example 14, from 3-p-/~[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethy1-2-naphthyl)propenyl]pheny1_7~(E)-2~propen-l-ol there can be obtained 3-p-/ [(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetra20 methy1-2-naphthyl)propenyl]phenyl_7“2“ProPen-l“Yl methyl ether of melting point 88°-90°C.
The following Examples illustrate pharmaceutical preparations provided by the invention:
Example A
Capsules for oral administration can contain the following ingredients:
Per capsule p-[ (E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester 0.1 mg
Wax mixture 50.5 mg
Vegetable oil 98.9 mg
Trisodium salt of ethylenediaminetetraacetic acid 0.5 mg
Example B
An ointment can have the following ρ-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester Cetyl alcohol
Lanolin
Vaseline
Distilled water q.s. ad composition:
0.01 g 2.7 g 6.0 g
.0 g 100.0 g
Claims (14)
- CLAIMS: , wherein n stands for 1 or 2 and, when, n 1 2 stands for 1, R and R represent hydrogen, lower alkoxy or halogen, or, when n stands for 2, R 1 represents hydrogen, lower alkoxy
- 2. 3 or halogen and R represents hydrogen; R . 4 5 6 R , R and R represent hydrogen or lower alkyl; R 7 represents hydrogen, methyl or 8 9 ethyl; R and R represent hydrogen, lower alkyl or halogen; and R 10 represents a 19 R 11 group of the formula —(CH=CR ) , in which m stands for zero or 1 and R 11 represents a group of the formula ,12 -CH-R' or the 2-oxa2olinyl group, or, when m stands 1 9 for 1, also represents hydrogen; R represents hydrogen or lower alkyl; R' represents hydrogen, lower alkyl or a group of the formula -N(R 17 ,R 18 ) or -OR 14 ; R 14 represents hydrogen, lower alkyl or alkanoyl; R 15 represents hydrogen, lower alkyl or a 5 group of the formula -OR 1 ® or —(CH,) N(R 17 , P 18 16 R ); R represents hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the 17 18 aryl portion; R and R represent 17 18 10 hydrogen or lower alkyl or R and R together with the nitrogen atom to which they are attached represent a heterocyclic 19 group; R represents hydrogen or lower alkyl and p stands for zero, 1, 2 or 3; as 15 well as ketals of compounds of formula I in which R represents a group of the formula 15 15 —C(O)R and R represents hydrogen or lower alkyl, and salts of compounds of formula I. 20 2) Compounds according to claim 1 in which, R 10 represents hydroxymethyl, alkoxynethyl, alkaneylaxynethyl, carboxyl, alkoxycarbonyl, formyl, alkylenedioxymethyl, alkanoyl, carbamoyl, mono(lower alkyl)carbamoyl, di(lower alkyl)carbamoyl, N-heterocyclylcarbonyl or 2-oxazolinyl, and salts thereof.
- 3. ) Compounds according to claim 1, wherein n stands for 5 2. T 2 5 6
- 4. ) Compounds according to claim 3, wherein R , R , R , R , 8 9 3 4 7 R and R represent hydrogen and R , R and R represent methyl.
- 5. ) Compounds according to claim 4, wherein R 10 represents 10 a group of the formula —(CHeCHj^R 11 .
- 6. ) Compounds according to claim 5, wherein m stands for zero.
- 7. ) Compounds according to claim 6, wherein R 11 represents lower alkoxycarbonyl, lower alkylcarbamoyl, lower alkoxy15 methyl or lower alkanoyloxymethyl.
- 8. ) ρ-[(E)-2-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester.
- 9. ) ρ-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl acetate. 20 10) ρ-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzyl methyl ether. ’ 47617 11) p /jE)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl7-benzoic acid monoethylamide. 12) A process for the manufacture of the compounds of formula I given in claim 1 and salts thereof, which process comprises reacting a compound of the general formula (II) (III) I 8 , 3 and n have the significance given in claim 1, and either A represents a triarylphosphoniumalkyl group of the formula 1 (+) (=) R-CH—Ρ [Qj .j Y , in which R represents a hydrogen atom or the methyl or ethyl group, Q represents an aryl group and Y represents the anion of an organic or inorganic acid, and B represents the formyl group; or A represents the formyl, acetyl or propionyl group and B represents a dialkoxyphosphiny1alkyl group of the formula R—CH—p[Z] 2 , in which R has the significance given earlier ,10 in this claim and Z represents a lower alkoxy group; to give a compound of formula I and, if desired, functionally modifying the group R 10 . 5 13) A process for the manufacture of the compounds of formula I given in claim 1 and salts thereof, substantially as hereinbefore described with reference to any one of Examples 1 to 38. 14) Compounds of formula I given in claim 1 and salts
- 10. Thereof, when manufactured by the process claimed in claim 12 or claim 13 or by an obvious chemical equivalent thereof.
- 11. 15) A pharmaceutical preparation containing a compound of formula I given in claim 1 or a salt thereof in association with a carrier material. 15
- 12. 16) A pharmaceutical preparation according to claim 15, wherein said compound of formula I is p-[(E)-2-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester.
- 13. 17) A pharmaceutical preparation according to claim 15,
- 14. 20 wherein said compound of formula I is p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthy1)propenyl]-benzyl methyl ether.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU78751 | 1977-12-22 | ||
CH1159078 | 1978-11-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE782472L IE782472L (en) | 1979-06-22 |
IE47617B1 true IE47617B1 (en) | 1984-05-02 |
Family
ID=25708596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2472/78A IE47617B1 (en) | 1977-12-22 | 1978-12-14 | Stilbene derivatives |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0002742B1 (en) |
JP (1) | JPS54109955A (en) |
AR (1) | AR224357A1 (en) |
AT (1) | AT361459B (en) |
AU (1) | AU525419B2 (en) |
BR (1) | BR7808470A (en) |
CA (1) | CA1123839A (en) |
CS (1) | CS208158B2 (en) |
CU (1) | CU35002A (en) |
CY (1) | CY1277A (en) |
DE (2) | DE2861748D1 (en) |
DK (1) | DK159967C (en) |
DO (1) | DOP1978002760A (en) |
ES (1) | ES476224A1 (en) |
FI (1) | FI68804C (en) |
FR (1) | FR2422620A1 (en) |
GB (1) | GB2010836B (en) |
GR (1) | GR71656B (en) |
HK (1) | HK30185A (en) |
HU (1) | HU180786B (en) |
IE (1) | IE47617B1 (en) |
IL (1) | IL56219A (en) |
IT (1) | IT1102753B (en) |
KE (1) | KE3504A (en) |
MC (1) | MC1230A1 (en) |
MY (1) | MY8500248A (en) |
NL (1) | NL7812312A (en) |
NO (1) | NO146322C (en) |
NZ (1) | NZ189203A (en) |
PT (1) | PT68965A (en) |
SE (1) | SE7813212L (en) |
SG (1) | SG5485G (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI67386C (en) * | 1979-06-21 | 1985-03-11 | Hoffmann La Roche | FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EQUIPMENT |
EP0084667B1 (en) * | 1982-01-23 | 1985-09-18 | BASF Aktiengesellschaft | Phenylethylene derivatives, their preparation and use as medicines |
US4588750A (en) * | 1982-07-02 | 1986-05-13 | Hoffmann-La Roche Inc. | Therapeutic compositions for reducing sebum secretion |
DK158947C (en) * | 1982-07-06 | 1991-01-21 | Hoffmann La Roche | TETRAHYDRONAPHTHALIN, BENZOFURAN AND BENZOTHIOPHENDER DERIVATIVES, PREPARATION AND USE THEREOF, AND RODENTICID CONTAINING SUCH DERIVATIVES |
US4808597A (en) * | 1983-07-05 | 1989-02-28 | Pfizer Inc. | Method for inhibiting the degradation of cartilage |
EP0155940A1 (en) * | 1983-08-08 | 1985-10-02 | Sri International | Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues |
FR2555571B1 (en) * | 1983-11-28 | 1986-11-28 | Interna Rech Dermatolo Centre | NAPHTHALENE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE THERAPEUTIC FIELD |
FR2562539B1 (en) * | 1984-04-06 | 1987-04-17 | Chauvin Blache Lab | NOVEL VINYL-4 BENZOIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATIONS THEREOF AND AS LIGANDS |
JPS6122046A (en) * | 1984-07-07 | 1986-01-30 | Koichi Shiyudo | Stilbene derivative |
EP0170105B1 (en) * | 1984-07-07 | 1990-10-17 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
DE3434942A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | TETRALINE DERIVATIVES, THEIR PRODUCTION AND USE |
DE3438386A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | PHOSPHORSAEUREVINYLBENZYLESTER, THEIR PRODUCTION AND USE |
DE3434944A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | L-SUBSTITUTED TETRALIN DERIVATIVES, THEIR PRODUCTION AND USE |
DE3434946A1 (en) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
DE3434948A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | VINYLTETRAZOLYLPHENYL DERIVATIVES, THEIR PRODUCTION AND USE |
LU85558A1 (en) * | 1984-09-28 | 1986-04-03 | Oreal | NOVEL RETINOICALLY ACTIVE NAPHTHALENIC DERIVATIVES, PREPARATION METHODS THEREOF, AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
LU85726A1 (en) * | 1985-01-10 | 1986-08-04 | Cird | NOVEL NAPHTHALENIC DERIVATIVES OF BENZONORBORNENE, PROCESS FOR THEIR PREPARATION AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM |
CA1268125A (en) * | 1985-06-28 | 1990-04-24 | F. Hoffmann-La Roche Ag | Use of a retinoid |
ZW7487A1 (en) * | 1986-05-23 | 1987-12-16 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
US4885282A (en) * | 1987-07-02 | 1989-12-05 | Thornfeldt Carl R | Treatment of hyperhidrosis, ichthyosis and wrinkling |
DE3726806A1 (en) * | 1987-08-12 | 1989-02-23 | Basf Ag | ARYLPHOSPHOR DERIVATIVES, THEIR PRODUCTION AND USE |
CA1298309C (en) * | 1987-11-06 | 1992-03-31 | Michael Klaus | Benzocycloheptene derivatives |
US5250562A (en) * | 1988-02-24 | 1993-10-05 | Hoffmann-La Roche Inc. | Stilbene derivatives |
KR0139216B1 (en) * | 1988-04-11 | 1998-05-01 | 제임스 엠. 캐내지 | Tetralin esters of phenols or benzoic acids having retinoic like activity |
DE3903993A1 (en) * | 1989-02-10 | 1990-08-16 | Basf Ag | DIARYL SUBSTITUTED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND MEDICINAL PRODUCTS THEREOF |
US5196532A (en) * | 1989-02-08 | 1993-03-23 | Basf Aktiengesellschaft | Diaryl-substituted heterocyclic compounds, their preparation and drugs and cosmetics obtained therefrom |
DE3903989A1 (en) * | 1989-02-10 | 1990-09-20 | Basf Ag | DIPHENYLHETEROALKYL DERIVATIVES, THEIR PREPARATION, AND MEDICAMENTS AND COSMETICS THEREOF |
DE3926148A1 (en) * | 1989-08-08 | 1991-02-28 | Basf Ag | DIARYLACETYLENE, THEIR MANUFACTURE AND USE |
JPH0579665U (en) * | 1992-03-27 | 1993-10-29 | 株式会社のもと | Reading assistance sheet |
CA2129773C (en) * | 1993-09-02 | 2007-05-01 | Michael Klaus | Aromatic carboxylic acid derivatives |
FR2743560B1 (en) | 1996-01-17 | 1998-04-03 | Europ De Bioprospective Centre | RETINOID-TYPE AROMATIC POLYCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL AND COSMETIC COMPOSITIONS |
US7226951B2 (en) * | 2003-12-17 | 2007-06-05 | Allergan, Inc. | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same |
JP5826459B2 (en) * | 2007-01-15 | 2015-12-02 | チョンシー ユー | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin permeability |
US20190112272A1 (en) * | 2016-04-07 | 2019-04-18 | High Force Research Limited | Synthetic retinoids for use in rar mediated conditions |
CN115667190A (en) * | 2020-06-17 | 2023-01-31 | 贝达药业股份有限公司 | Bicyclic compounds and application thereof |
-
1978
- 1978-11-29 DK DK536178A patent/DK159967C/en not_active IP Right Cessation
- 1978-12-08 CA CA317,610A patent/CA1123839A/en not_active Expired
- 1978-12-14 IE IE2472/78A patent/IE47617B1/en not_active IP Right Cessation
- 1978-12-15 EP EP78101700A patent/EP0002742B1/en not_active Expired
- 1978-12-15 DE DE7878101700T patent/DE2861748D1/en not_active Expired
- 1978-12-15 FI FI783863A patent/FI68804C/en not_active IP Right Cessation
- 1978-12-15 IL IL56219A patent/IL56219A/en not_active IP Right Cessation
- 1978-12-15 DE DE19782854354 patent/DE2854354A1/en not_active Withdrawn
- 1978-12-18 NZ NZ189203A patent/NZ189203A/en unknown
- 1978-12-19 FR FR7835651A patent/FR2422620A1/en active Granted
- 1978-12-19 NL NL7812312A patent/NL7812312A/en not_active Application Discontinuation
- 1978-12-19 MC MC781349A patent/MC1230A1/en unknown
- 1978-12-20 GR GR27943A patent/GR71656B/el unknown
- 1978-12-20 HU HU78HO2122A patent/HU180786B/en not_active IP Right Cessation
- 1978-12-20 CS CS788627A patent/CS208158B2/en unknown
- 1978-12-21 JP JP15699278A patent/JPS54109955A/en active Granted
- 1978-12-21 CY CY1277A patent/CY1277A/en unknown
- 1978-12-21 PT PT68965A patent/PT68965A/en unknown
- 1978-12-21 SE SE7813212A patent/SE7813212L/en not_active Application Discontinuation
- 1978-12-21 ES ES476224A patent/ES476224A1/en not_active Expired
- 1978-12-21 AT AT917578A patent/AT361459B/en not_active IP Right Cessation
- 1978-12-21 NO NO784329A patent/NO146322C/en unknown
- 1978-12-21 AR AR274941A patent/AR224357A1/en active
- 1978-12-21 GB GB7849418A patent/GB2010836B/en not_active Expired
- 1978-12-22 BR BR7808470A patent/BR7808470A/en unknown
- 1978-12-22 DO DO1978002760A patent/DOP1978002760A/en unknown
- 1978-12-22 IT IT7831277A patent/IT1102753B/en active
- 1978-12-22 AU AU42861/78A patent/AU525419B2/en not_active Ceased
- 1978-12-25 CU CU7835002A patent/CU35002A/en unknown
-
1985
- 1985-01-22 SG SG54/85A patent/SG5485G/en unknown
- 1985-02-18 KE KE3504A patent/KE3504A/en unknown
- 1985-04-18 HK HK301/85A patent/HK30185A/en unknown
- 1985-12-30 MY MY248/85A patent/MY8500248A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4326055A (en) | Stilbene derivatives | |
IE47617B1 (en) | Stilbene derivatives | |
FI66587C (en) | FRAMEWORK FOR THE PROCESSING OF THERAPEUTIC MEDICINAL PRODUCTS | |
US4539154A (en) | Polyene compounds | |
US4678793A (en) | Heterocyclic compounds | |
US4994489A (en) | Ester derivatives of diarylacetylenes, their compositions and their use in acne treatment | |
JP2556577B2 (en) | Novel stilbene derivative | |
US3781314A (en) | Polyene compounds | |
NO171158B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZOCYCLYLOHEPTEND DERIVATIVES | |
NZ199649A (en) | Tetrahydronaphthalene and indane compounds and pharmaceutical compositions | |
US4267382A (en) | 2,6-Dichloro-4-methoxy-5-methyl-benzene aldehydes | |
GB1563732A (en) | Polyene compounds | |
US4163103A (en) | Novel derivatives of 9-substituted phenyl-3,7-dimethyl-nona-2,4,6,8-tetraene | |
GB2122200A (en) | Polyene compounds | |
Hunadi et al. | Methano-bridged 14. pi.-electron aromatic annulenes. 2. 5-Methoxy-7, 12-methano-6-azabenz [10] annulene and the benzenesulfonate ester of 5-hydroxy-7, 12-methano-6-azabenz [10] annulene | |
KR820002075B1 (en) | Process for the preparation of stilbene derivatives | |
KR820000457B1 (en) | Process for preparation of polyene compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |